• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Malaysia·Consumer Cyclical·DQWS
Share

DSwiss, Inc. Stocks

$ 0.08Last Updated 17.09.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

$ 16.55M

$ 0.08
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

DSwiss, Inc. is a biotech-nutraceutical company that supplies a comprehensive range of health and beauty products. Its market reach extends across Malaysia, Singapore, Indonesia, Taiwan, Macau, Hong Kong, and China. The company's product line includes specialized items like DSwiss coffee, targeting digestive well-being, and DSwiss kiwi, formulated to boost the immune system, improve skin tone, help manage blood pressure, and minimize the risk of heart disease and stroke. DSwiss Triple SC focuses on stem cell-related benefits. For skincare, DSwiss offers the DSwiss silk mask, designed for dry, damaged, and sensitive skin; the DSwiss coffee slimming scrub, a natural body exfoliant for removing impurities; the cooling DSwiss peppermint slimming gel; the DSwiss new age essence, which provides nutrients to moisturize, brighten, and refresh tired-looking skin; and the DSwiss enlighten essence cream, a light, nourishing formula. DSwiss also provides medical eyewear under the name DSwiss BioSpec. Its broader health offerings include Genmune-Pro, which strengthens the human immune system by enhancing digestive health; SkinEra, a solution for various skin conditions such as acne, pimples, atopic dermatitis, dry skin, and allergic rashes; SensiBath gel; and SuiSu hand purifiers, sanitizers, and air sanitizers. Specialized supplements include MasterLiv for liver support, MasterHeart for maintaining optimal heart health and smooth blood circulation, and WellG, which delivers essential nutrients for sugar metabolism and energy production. In addition to its product range, DSwiss, Inc. offers diagnostic and analytical equipment. This includes the DSwiss quantum magnetic analyzer, a device that interprets body energy fields to assess health status and offer recommendations, and an AI skin analyzer machine, a facial camera designed to collect skin image data. The company also provides turnkey private label manufacturing services and DNA microarray genotyping services. Furthermore, DSwiss supplies a variety of medical consumables, such as surgical gowns and gloves, 3-ply face masks, N95 masks, protective goggles, body infrared thermometers, disposable bedsheets, and stretcher covers. DSwiss, Inc. was incorporated in 2015 and is headquartered in Kuala Lumpur, Malaysia.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.09.2026 10:56

FT: The U.S. Backed Chelsea's Former Co-Owner in His Battle with Carlyle Over Lukoil Assets

23.09.2026 10:45

Hawkish Easing: Why BofA Is Betting on Forward Contracts in Kazakhstan

23.09.2026 10:37

Top Stories This Morning: OpenAI and Anthropic Have Made Their AI Models More Affordable; Qualcomm Unveiled a New Chip

23.09.2026 09:00

Apple is developing a new type of device, according to Bloomberg. What is known about the gadget?

23.09.2026 07:30

In the U.S., a second IPO has been canceled in less than a week. Why is this a cause for concern?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026